Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001841619 XXXXXXXX LIVE 3 Common Stock 08/17/2026 false 0001787740 888705308 Valion Bio, Inc. 1305 E. Houston Street, Building 1 Suite 311 San Antonio TX 78205 Maier J. Tarlow (646) 845-0040 2 Wooster Street, 2nd Floor New York NY 10013 0001841619 N 3i, LP a WC N DE 0.00 2050200.00 0.00 2050200.00 2050200.00 N 9.9 PN As more fully described in Item 5 of this Amendment No. 3 (as defined in Item 1 below), such shares and percentage are based on 18,892,969 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") outstanding, consisting of (a) 4,151,259 shares of Common Stock as of July 7, 2026 as disclosed in the definitive proxy statement filed by the Issuer with the U.S. Securities and Exchange Commission ("SEC") on July 17, 2026 (the "Proxy Statement"), (b) 256,105 shares of Common Stock issued to 3i, LP on July 19, 2026 pursuant to conversions of certain shares of Series B Preferred Stock (as defined below), (c) 846,666 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (d) 9,260,042 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series C Preferred Stock (as defined below), (e) 1,262,733 shares of Common Stock issued to 3i, LP on August 13, 2026 pursuant to conversion of certain shares of Series C Preferred Stock, and (f) 3,116,164 shares of Common Stock issued to 3i, LP on August 17, 2026 pursuant to conversion of certain shares of Series C Preferred Stock. Beneficial ownership consists of 420,641 shares of Common Stock directly held by 3i, LP and 1,629,559 shares of Common Stock issuable in any combination upon (i) exercises of certain common stock purchase warrants (the "Warrants") held directly by 3i, LP, which exercises are subject to a 9.99% beneficial ownership limitation provision (a "Blocker"), (ii) conversions of a senior secured convertible note in the original principal amount of $16,253,147.10 (the "Note") held directly by 3i, LP, which conversions are subject to a Blocker, (iii) conversions of shares of Series B Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series B Preferred Stock") directly held by 3i, LP, which conversions are subject to a Blocker, and (iv) conversions of shares of Series C Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series C Preferred Stock") directly held by the 3i, LP, which conversions are subject to a Blocker. Y Tumim Stone Capital, LLC a WC N DE 0.00 0.00 0.00 0.00 0.00 N 0.0 OO Y 3i Management LLC a WC N DE 0.00 2050200.00 0.00 2050200.00 2050200.00 N 9.9 OO As more fully described in Item 5 of this Amendment No. 3, such shares and percentage are based on 18,892,969 shares of Common Stock outstanding, consisting of (a) 4,151,259 shares of Common Stock as of July 7, 2026 as disclosed in the Proxy Statement, (b) 256,105 shares of Common Stock issued to 3i, LP on July 19, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (c) 846,666 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (d) 9,260,042 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series C Preferred Stock, (e) 1,262,733 shares of Common Stock issued to 3i, LP on August 13, 2026 pursuant to conversions of certain shares of Series C Preferred Stock and (f) 3,116,164 shares of Common Stock issued to 3i, LP on August 17, 2026 pursuant to conversions of certain shares of Series C Preferred Stock. Beneficial ownership consists of 420,641 shares of Common Stock indirectly held by the reporting person and 1,629,559 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker. Y Maier J. Tarlow a WC N X1 0.00 2050200.00 0.00 2050200.00 2050200.00 N 9.9 IN As more fully described in Item 5 of this Amendment No. 3, such shares and percentage are based on 18,892,969 shares of Common Stock outstanding, consisting of (a) 4,151,259 shares of Common Stock as of July 7, 2026 as disclosed in the Proxy Statement, (b) 256,105 shares of Common Stock issued to 3i, LP on July 19, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (c) 846,666 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (d) 9,260,042 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series C Preferred Stock, (e) 1,262,733 shares of Common Stock issued to 3i, LP on August 13, 2026 pursuant to conversions of certain shares of Series C Preferred Stock and (f) 3,116,164 shares of Common Stock issued to 3i, LP on August 17, 2026 pursuant to conversions of certain shares of Series C Preferred Stock. Beneficial ownership consists of 420,641 shares of Common Stock indirectly held by the reporting person and 1,629,559 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker. Common Stock Valion Bio, Inc. 1305 E. Houston Street, Building 1 Suite 311 San Antonio TX 78205 This Amendment No. 3 to Schedule 13D (this "Amendment No. 3") relates to the common stock, par value $0.0001 per share (the "Common Stock") of Valion Bio, Inc., a Delaware corporation (the "Issuer"), and amends the Schedule 13D filed on August 3, 2026, as amended by Amendment No. 1 filed on August 11, 2026 and Amendment No. 2 filed on August 14, 2026 (as amended, the "Original Schedule 13D") by (a) 3i, LP, (b) Tumim Stone Capital, LLC ("Tumim Stone"), (c) 3i Management LLC ("3i Management") and (d) Maier J. Tarlow ("Mr. Tarlow" and, together with 3i, LP, 3i Management and Tumim Stone, the "Reporting Persons") as set forth herein. This Item 2(a) is not being amended by this Amendment No. 3. This Item 2(b) is not being amended by this Amendment No. 3. This Item 2(c) is not being amended by this Amendment No. 3. This Item 2(d) is not being amended by this Amendment No. 3. This Item 2(e) is not being amended by this Amendment No. 3. This Item 2(f) is not being amended by this Amendment No. 3. This Item 3 is not being amended by this Amendment No. 3. Item 4 of the Original Schedule 13D is hereby amended to add the following paragraph at the end thereof: On August 17, 2026, the Issuer and 3i, LP entered into a letter agreement (the "Letter Agreement"), pursuant to which the Issuer issued to 3i, LP 1,500 shares of Series B Preferred Stock at $1,000 per share and (b) Warrants to purchase 1,153,847 shares of Common Stock at an initial exercise price of $0.23708 per share for no additional consideration, for an aggregate purchase price of $1,500,000. The Issuer and 3i, LP are continuing to negotiate in good faith additional tranches of funding but there are no definitive agreements or understandings that are currently in place between the parties. Item 5(a) of the Original Schedule 13D is hereby amended and restated as follows: See rows (11) and (13) of the cover pages to this statement for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons. The shares and percentages are based on 18,892,969 shares of Common Stock outstanding, consisting of (a) 4,151,259 shares of Common Stock as of July 7, 2026 as disclosed in the Proxy Statement, (b) 256,105 shares of Common Stock issued to 3i, LP on July 19, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (c) 846,666 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (d) 9,260,042 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series C Preferred Stock, (e) 1,262,733 shares of Common Stock issued to 3i, LP on August 13, 2026 pursuant to conversions of certain shares of Series C Preferred Stock and (f) 3,116,164 shares of Common Stock issued to 3i, LP on August 17, 2026 pursuant to conversions of certain shares of Series C Preferred Stock. This Item 5(b) is not being amended by this Amendment No. 3. This Item 5(c) is hereby amended to add the transactions set forth in Exhibit 6 attached herein. This Item 5(d) is not being amended by this Amendment No. 3. This Item 5(e) is not being amended by this Amendment No. 3. This Item 6 is not being amended by this Amendment No. 3. Item 7 of the Original Schedule 13D is hereby amended to add the following exhibits: Exhibit 6: Additional Transactions Exhibit 7: Letter Agreement between the Issuer and 3i, LP, dated August 17, 2026 (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the SEC on August 17, 2026) 3i, LP /s/ Maier J. Tarlow Maier J. Tarlow, manager of 3i Management LLC, general partner of 3i, LP 08/19/2026 Tumim Stone Capital, LLC /s/ Maier J. Tarlow Maier J. Tarlow, manager of 3i Management LLC, manager of Tumim Stone Capital, LLC 08/19/2026 3i Management LLC /s/ Maier J. Tarlow Maier J. Tarlow, Manager 08/19/2026 Maier J. Tarlow /s/ Maier J. Tarlow Maier J. Tarlow 08/19/2026